HC Wainwright Predicts PepGen’s Q1 Earnings (NASDAQ:PEPG)

PepGen, Inc. (NASDAQ:PEPG) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for PepGen in a note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of ($0.52) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.52) EPS and Q4 2026 earnings at ($0.52) EPS.

PEPG has been the subject of several other research reports. Guggenheim reissued a “buy” rating and issued a $6.00 price target on shares of PepGen in a research note on Wednesday, September 24th. Wedbush upped their target price on PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of PepGen in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus boosted their price objective on PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Four analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, PepGen presently has an average rating of “Hold” and an average target price of $10.00.

PepGen Stock Performance

Shares of PepGen stock traded down $0.05 during trading on Friday, hitting $4.84. 58,176 shares of the stock were exchanged, compared to its average volume of 1,897,136. The stock’s fifty day moving average is $3.94 and its 200 day moving average is $2.25. The stock has a market cap of $158.88 million, a PE ratio of -1.71 and a beta of 1.95. PepGen has a 12 month low of $0.88 and a 12 month high of $6.85.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11.

Insider Buying and Selling at PepGen

In related news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The stock was acquired at an average price of $3.20 per share, for a total transaction of $640,000.00. Following the completion of the acquisition, the insider owned 4,955,388 shares of the company’s stock, valued at $15,857,241.60. This represents a 4.21% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in PepGen by 88.7% in the third quarter. Vanguard Group Inc. now owns 1,768,356 shares of the company’s stock worth $8,170,000 after buying an additional 831,333 shares during the last quarter. Woodline Partners LP bought a new position in PepGen during the first quarter valued at approximately $1,097,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of PepGen by 68.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,350,000 shares of the company’s stock worth $1,897,000 after buying an additional 550,000 shares during the period. Monashee Investment Management LLC bought a new stake in PepGen during the 3rd quarter valued at $1,386,000. Finally, UBS Group AG lifted its holdings in PepGen by 1,714.5% in the 3rd quarter. UBS Group AG now owns 242,451 shares of the company’s stock worth $1,120,000 after buying an additional 229,089 shares during the period. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.